Pediatrix Medical Group Inc (MD)

Generated: April 15, 2026

✅ Pass

Business Overview

Pediatrix Medical Group is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal, and pediatric subspecialty care^[2]. The company generates revenue by providing physician services across these specialized pediatric segments. In Q4 2025, Pediatrix reported revenue of $493.8 million, though sales declined 1.7% year-over-year^[1]. The company operates as a consolidator of pediatric medical practices, leveraging scale to manage costs while delivering specialized clinical services to hospitals and healthcare systems.

Non-Recurring Revenue

Based on available search results, there is no evidence of material one-time, non-recurring revenue events in fiscal 2024 or 2025 that artificially inflated reported results. Q4 2025 results showed revenue that slightly beat analyst expectations ($493.8 million versus $487.3 million estimated), but this represents normal quarterly variance rather than a non-recurring windfall^[1]. The company's earnings miss on a non-GAAP basis ($0.50 per share versus $0.54 expected) further suggests results were driven by operational performance rather than one-off gains^[1]. No asset sales, legal settlements, or government stimulus payments are mentioned in recent filings or earnings reports. The reported results appear to reflect underlying business performance without material distortion from non-recurring items.

Short-Seller & Fraud Risk

No significant short-seller reports, fraud accusations, accounting irregularities, or regulatory investigations are evident in the available search results. The company does not appear to qualify as a "battleground stock" based on the information provided. Institutional investors own 97.71% of outstanding shares^[2], suggesting strong institutional confidence. Recent analyst activity shows a consensus "Hold" rating from seven analysts (five holds, one buy, one strong buy) as of April 2026^[2], indicating mainstream coverage without controversy. No securities class-action lawsuits or material regulatory concerns are mentioned. The company's SEC filings appear routine, with standard 8-K and 10-K disclosures^[3]^[5]. Overall, Pediatrix presents no apparent fraud or short-seller risk profile.

Financial Health

Pediatrix maintains a solid balance sheet with $499.7 million in cash against $634.6 million in debt as of the most recent quarter^[1]. The company's net-debt-to-EBITDA ratio of 0.5× is considered safe, with trailing twelve-month EBITDA of $275.6 million^[1]. Annual interest expenses of $4.14 million are modest relative to operating cash generation, and the interest coverage ratio stands at 6.53×^[4], indicating comfortable debt servicing capacity. The current ratio of 1.83 and quick ratio of 1.78 demonstrate adequate short-term liquidity^[4]. No material debt maturities or refinancing risks are flagged in recent disclosures. The company's debt-to-equity ratio of 0.66 is moderate for the healthcare sector^[2]. No covenant violations, credit downgrades, or signs of financial distress are evident. Financial health appears stable.

Cyclicality Risk

Pediatrix operates in pediatric healthcare services, which is not inherently cyclical in the traditional sense. Demand for high-acuity newborn and maternal-fetal care is driven by demographic factors and clinical need rather than economic cycles. However, the company faces volume headwinds: Q4 2025 revenue declined 1.7% year-over-year, and estimated sales for the next 12 months are flat, implying a softer demand environment^[1]. Operating margins have improved significantly, rising 10.5 percentage points over the last two years to 10.9% on a trailing twelve-month basis^[1], suggesting the company is offsetting volume weakness through pricing and operational efficiency. This margin expansion is not indicative of cyclical peak pricing but rather structural margin improvement. The healthcare services sector is generally non-cyclical, and Pediatrix's current challenges appear demand-specific rather than cyclically driven.

Sources

Featured in MagicDiligence Analysis

Magic Formula Screen - April 22, 2026 April 22, 2026